Nuvalent Inc. (NUVL)
70.97
-2.08 (-2.85%)
At close: Mar 31, 2025, 3:59 PM
70.92
-0.07%
After-hours: Mar 31, 2025, 04:40 PM EDT
-2.85% (1D)
| Bid | 67.13 |
| Market Cap | 5.08B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -262.37M |
| EPS (ttm) | -3.93 |
| PE Ratio (ttm) | -18.06 |
| Forward PE | -19.46 |
| Analyst | Buy |
| Ask | 74.76 |
| Volume | 725,478 |
| Avg. Volume (20D) | 507,059 |
| Open | 72.42 |
| Previous Close | 73.05 |
| Day's Range | 67.61 - 72.39 |
| 52-Week Range | 61.80 - 113.51 |
| Beta | 1.42 |
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 142
Stock Exchange NASDAQ
Ticker Symbol NUVL
Website https://www.nuvalent.com
Analyst Forecast
According to 10 analyst ratings, the average rating for NUVL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 55.00% from the latest price.
Stock Forecasts6 months ago
-6.61%
Nuvalent shares are trading lower after the compan...
Unlock content with
Pro Subscription
6 months ago
+28.27%
Nuvalent shares are trading higher after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs and accelerated its development timeline. Also, the company announced a $350 million public offering and multiple firms raised their respective price targets on the stock.
